A large study involving nearly 10,000 elderly individuals, around 74.7 years old, who had no history of cardiovascular disease and normal blood test results, found that taking a statin called atorvastatin significantly reduced the risk of cardiovascular events by 30%. The research, conducted by Australian scientists and published in the New England Journal of Medicine, followed participants for six years. It compared those who took atorvastatin with those who received a placebo, a substance with no active ingredients. Over the study period, there were 10.9 cardiovascular events per 1,000 people in the statin group, compared to 15.5 in the placebo group. The study did not find any significant effect of statins on dementia, physical disability, or overall mortality. This means that while the drugs helped prevent heart-related issues, they did not appear to improve brain health, mobility, or reduce the risk of death from causes other than cardiovascular disease. The findings suggest that statins may be effective in reducing heart-related risks, but they do not necessarily extend healthy life expectancy or reduce overall death rates. Side effects were similar between the two groups, with 63% of participants on atorvastatin and 58.7% on the placebo reporting some kind of side effect. Treatment discontinuation rates were also close, with 7.2% of those on atorvastatin and 6.1% on the placebo stopping the treatment. This suggests that the side effects were not significantly worse for those taking the statin, even though the drug was effective in reducing heart-related events. The study adds to the ongoing discussion about the benefits and risks of statin use in older adults without existing cardiovascular disease. While the drugs are widely used to lower cholesterol and prevent heart problems, this research highlights that their benefits are specific to cardiovascular health and do not extend to other aspects of aging or longevity. The findings may help guide treatment decisions for older individuals considering statin therapy.